Myocet Technologies

Myocet Technologies is a specialty biotechnology company and a subsidiary of GP-Pharm, focused on the development and manufacturing of complex liposomal drug delivery systems. The company is primarily recognized for its role in the production and technical management of Myocet, a non-pegylated liposomal doxorubicin formulation indicated for the treatment of metastatic breast cancer. By utilizing advanced liposomal technology, the company aims to enhance the therapeutic index of cytotoxic agents, reducing systemic toxicity while maintaining efficacy. Myocet Technologies provides specialized manufacturing services and intellectual property management for complex injectable products within the oncology and specialty medicine sectors. Its facilities are equipped for the production of high-potency compounds under stringent GMP standards.